| Symbol | APLM |
|---|---|
| Name | APOLLOMICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 989 E. HILLSDALE BLVD.,SUITE 220, FOSTER CITY, California, 94404, United States |
| Telephone | 650 209 4055 |
| Fax | — |
| — | |
| Website | https://www.apollomicsinc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001944885 |
| Description | Apollomics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics has a pipeline of approximately nine drug candidates across multiple programs, six of which are in the clinical-stage of development. Apollomics lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is in a Phase II multicohort clinical trial in the United States. The Company is also developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers. Additional info from NASDAQ: |
New Form 3 - Apollomics Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001193125-26-316489 <b>Size:</b> 4 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreApollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Read moreLIN PETER KUAN-HOW 🟡 adjusted position in 3.6K shares (1 derivative) of Apollomics Inc. (APLM) at $13.85 Transaction Date: Jun 15, 2026 | Filing ID: 274552
Read moreChen Hung-Wen 🟡 adjusted position in 0 shares (1 derivative) of Apollomics Inc. (APLM) Transaction Date: Jun 15, 2026 | Filing ID: 272860
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05367388 | A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Hea… | Phase1 | Bioequivalence | Unknown | 2022-05-20 | 2022-12-01 | ClinicalTrials.gov |
| NCT04743505 | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients… | Phase1 | Metastatic Non Small Cell Lung Cancer | Active_Not_Recruiting | 2022-01-18 | 2029-12-31 | ClinicalTrials.gov |
| NCT05054543 | Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy … | Phase3 | Relapsed/Refractory AML | Terminated | 2021-11-17 | 2024-08-22 | ClinicalTrials.gov |
| NCT05055518 | APL-102 Capsule in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Suspended | 2021-08-02 | 2028-12-31 | ClinicalTrials.gov |
| NCT04839341 | Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to … | Phase1 | Relapsed/Refractory AML | Completed | 2021-02-24 | 2024-06-28 | ClinicalTrials.gov |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metasta… | Phase1 | Hepatocellular Carcinoma | Terminated | 2018-09-05 | 2021-12-15 | ClinicalTrials.gov |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Me… | Phase2 | Solid Tumors | Recruiting | 2017-09-27 | 2026-11-30 | ClinicalTrials.gov |
| NCT03053466 | APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | Phase1 | Solid Tumor | Completed | 2017-03-27 | 2022-02-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nivolumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-501 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| Nivolumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-501 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-501 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03053466 |
| APL-501 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03053466 |
| PLB-1001 | Other | Phase PHASE1 | Bioequivalence | UNKNOWN | NCT05367388 |
| APL-101 | Other | Phase PHASE1 | Bioequivalence | UNKNOWN | NCT05367388 |
| APL-102 Capsules | Other | Phase PHASE1 | Advanced Solid Tumor | SUSPENDED | NCT05055518 |
| Placebo | Other | Phase PHASE3 | Relapsed/Refractory AML | TERMINATED | NCT05054543 |
| Uproleselan | Other | Phase PHASE3 | Relapsed/Refractory AML | TERMINATED | NCT05054543 |
| Uproleselan | Other | Phase PHASE1 | Relapsed/Refractory AML | COMPLETED | NCT04839341 |
| APL-101 Oral Capsules | Other | Phase PHASE2 | Solid Tumors | RECRUITING | NCT03175224 |
| Osimertinib | Other | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04743505 |
| APL-101 | Other | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04743505 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-501 | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| PLB-1001 | DRUG | Phase PHASE1 | Bioequivalence | UNKNOWN | NCT05367388 |
| APL-102 Capsules | DRUG | Phase PHASE1 | Advanced Solid Tumor | SUSPENDED | NCT05055518 |
| Placebo | DRUG | Phase PHASE3 | Relapsed/Refractory AML | TERMINATED | NCT05054543 |
| Uproleselan | DRUG | Phase PHASE3 | Relapsed/Refractory AML | TERMINATED | NCT05054543 |
| Osimertinib | DRUG | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04743505 |
| APL-101 | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT03655613 |
| APL-101 Oral Capsules | DRUG | Phase PHASE2 | Solid Tumors | RECRUITING | NCT03175224 |